Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
0.54% $3.72
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 313.09 mill |
EPS: | -1.630 |
P/E: | -2.28 |
Earnings Date: | May 05, 2024 |
SharesOutstanding: | 84.16 mill |
Avg Daily Volume: | 0.416 mill |
RATING 2024-04-19 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.28 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.39x |
Company: PE -2.28 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.696 (-54.41%) $-2.02 |
Date: 2024-04-20 |
Expected Trading Range (DAY) |
---|
$ 3.53 - 3.91 ( +/- 5.13%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-31 | Corcoran Andrea | Buy | 44 367 | Common Stock |
2024-02-01 | Corcoran Andrea | Sell | 15 843 | Common Stock |
2024-01-31 | Corcoran Andrea | Buy | 200 000 | Stock Option (Right to Buy) |
2024-01-31 | Corcoran Andrea | Sell | 44 367 | Restricted Stock Units |
2024-01-31 | Sommadossi Jean-pierre | Buy | 448 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
72.90 |
Last 99 transactions |
Buy: 22 764 762 | Sell: 12 804 280 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.72 (0.54% ) |
Volume | 0.211 mill |
Avg. Vol. | 0.416 mill |
% of Avg. Vol | 50.60 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.27 | N/A | Active |
---|
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.